Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.
Journal article
Casalin I. et al, (2024), Adv Biol Regul
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Journal article
Stahl M. et al, (2023), Blood Rev, 62
Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies
Journal article
Tatwavedi D. et al, (2023), Advances in Biological Regulation, 100993 - 100993
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Journal article
Bewersdorf JP. et al, (2023), Blood Rev, 60
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Journal article
Mongiorgi S. et al, (2023), Clin Epigenetics, 15
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.
Journal article
Robbe P. et al, (2022), Nat Genet, 54, 1675 - 1689
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Journal article
Zeidan AM. et al, (2022), Leukemia
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
Journal article
Stahl M. et al, (2022), Blood Adv
Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Journal article
Pellagatti A. and Boultwood J., (2022), Adv Biol Regul
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Journal article
Choudhary GS. et al, (2022), Elife, 11
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Journal article
Adema V. et al, (2022), EBioMedicine, 80
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.
Journal article
Gorombei P. et al, (2021), Int J Mol Sci, 22
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Journal article
Rahmani NE. et al, (2021), Blood Cancer Journal, 11
MDS DISEASE PROGRESSION: INSIGHTS FROM THE TRANSCRIPTOME
Conference paper
Boultwood J., (2021), LEUKEMIA RESEARCH, 108, S56 - S56
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Journal article
Bernard E. et al, (2021), Nat Med, 27
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism.
Journal article
Ueda K. et al, (2021), Cancer Cell
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Journal article
Bernard E. et al, (2021), Nat Med, 27
The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence.
Journal article
Smith H. et al, (2021), Int J Biochem Cell Biol
SF3B1 mutant myelodysplastic syndrome: Recent advances.
Journal article
Pellagatti A. and Boultwood J., (2020), Adv Biol Regul
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.
Journal article
Bailey MH. et al, (2020), Nat Commun, 11